These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33727795)

  • 1. The Use of Novel Non-Vitamin K Antagonist Oral Anticoagulants Following Closure of the Left Atrial Appendage: Preliminary Results of Clinical Follow-Up.
    Zhu J; Xu J
    Drug Des Devel Ther; 2021; 15():1067-1073. PubMed ID: 33727795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure.
    Chen Y; Zhang Y; Qu L; Huang W; Su X; Chen Y
    J Thromb Thrombolysis; 2021 Oct; 52(3):872-879. PubMed ID: 33666825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device.
    Fu G; Wang B; He B; Yu Y; Wang Z; Feng M; Liu J; Du X; Zhuo W; Chu H
    J Formos Med Assoc; 2022 Aug; 121(8):1488-1494. PubMed ID: 34740490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk.
    Godino C; Melillo F; Bellini B; Mazzucca M; Pivato CA; Rubino F; Figini F; Mazzone P; Della Bella P; Margonato A; Colombo A; Montorfano M
    EuroIntervention; 2020 Apr; 15(17):1548-1554. PubMed ID: 31845892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of left atrial appendage closure in atrial fibrillation patients with different types of heart failure.
    Liu L; Yan W; Xu X; Wan C; Liu F; Yao Q; Song L; Wang B; Song Z; Li H
    BMC Cardiovasc Disord; 2024 Aug; 24(1):430. PubMed ID: 39148039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
    Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
    Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 9. Perioperative Treatment with Rivaroxaban and Dabigatran on Changes of Coagulation and Platelet Activation Biomarkers following Left Atrial Appendage Closure.
    Yao Y; Li Y; Jin Q; Li X; Zhang X; Lv Q
    Cardiovasc Ther; 2024; 2024():4405152. PubMed ID: 38505191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device.
    Enomoto Y; Gadiyaram VK; Gianni C; Horton RP; Trivedi C; Mohanty S; Di Biase L; Al-Ahmad A; Burkhardt JD; Narula A; Janczyk G; Price MJ; Afzal MR; Atoui M; Earnest M; Swarup V; Doshi SK; van der Zee S; Fisher R; Lakkireddy DR; Gibson DN; Natale A; Reddy VY
    Heart Rhythm; 2017 Jan; 14(1):19-24. PubMed ID: 27771552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of different anticoagulation regimens after left atrial appendage occlusion.
    Li W; Gao R; Zhao J; Ren Y; Chen G; Zhu J; Jin K; Zhu L; Ruan Z
    Ann Palliat Med; 2022 Jan; 11(1):201-209. PubMed ID: 35144411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
    Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
    J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke prevention of thoracoscopic left atrial appendage clipping in patients with non-valvular atrial fibrillation at high risk of stroke and bleeding: study protocol for a non-randomised controlled clinical trial.
    Ye C; Han X; Chen Y; Liu F; Ma H; Yang Y; Liu Y; Hu Q; Yao Q; Xie W; Xu D
    BMJ Open; 2022 Oct; 12(10):e063931. PubMed ID: 36307161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.